Madrigal Pharmaceuticals (NASDAQ:MDGL) Rating Reiterated by JMP Securities
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report)‘s stock had its “market outperform” rating reiterated by investment analysts at JMP Securities in a report released on Friday, Benzinga reports. They currently have a $347.00 target price on the biopharmaceutical company’s stock. JMP Securities’ price objective suggests a potential upside of 46.70% from the stock’s current price. […]
More Stories
SuRo Capital (NASDAQ:SSSS) & BNY Mellon Strategic Municipal Bond Fund (NYSE:DSM) Head to Head Analysis
BNY Mellon Strategic Municipal Bond Fund (NYSE:DSM – Get Free Report) and SuRo Capital (NASDAQ:SSSS – Get Free Report) are...
LogProStyle Inc. (Kabushiki Kaisha LogProstyle) (LGPS) Announces January 16th IPO
LogProStyle Inc. (Kabushiki Kaisha LogProstyle) (LGPS) expects to raise $12 million in an IPO on Thursday, January 16th, IPO Scoop...
Top humanitarian official issues ceasefire appeal during visit to Gaza City
The UN Humanitarian Coordinator for the Occupied Palestinian Territory called on Sunday for an end to the war in Gaza...
Comparing AGC (OTCMKTS:ASGLY) & Sonic Healthcare (OTCMKTS:SKHHY)
AGC (OTCMKTS:ASGLY – Get Free Report) and Sonic Healthcare (OTCMKTS:SKHHY – Get Free Report) are both mid-cap industrial products companies,...
Comparing South Bow (SOBO) and Its Rivals
South Bow (NYSE:SOBO – Get Free Report) is one of 21 public companies in the “Pipelines, Except Natural Gas” industry,...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...